Precision BioSciences posts first patient biopsy data proving Hepatitis B viral elimination
Precision BioSciences (NASDAQ:DTIL) unveiled late-breaking clinical data from its ongoing Phase 1/2a ELIMINATE-B trial, delivering what it characterizes as the first-ever human biopsy evidence of a therapeutic agent successfully eliminating and inactivating the root genetic reservoir of chronic hepatitis B.


_1407476_640x360_2501505091693-640x360.webp&w=3840&q=75)


_1407456_640x360_2501504067584-640x360.webp&w=3840&q=75)
_1407422_640x360_2501497411628-640x360.webp&w=3840&q=75)
_1407420_640x360_2501496387756-640x360.webp&w=3840&q=75)



_1407405_640x360_2501491779876-640x360.webp&w=3840&q=75)